CMBA
AGIO icon

C.M. Bidwell & Associates’s Agios Pharmaceuticals AGIO Stock Holding History

C.M. Bidwell & Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85
Closed -$2.1K – 494
2023
Q3 		$2.1K Sell
85
-6,260
-99% -$166K ﹤0.01% 453
2023
Q2 		$180K Buy
+6,345
New +$158K 0.13% 134

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

C.M. Bidwell & Associates's AGIO Position: Q4 2023 in Review

C.M. Bidwell & Associates sold out of Agios Pharmaceuticals (AGIO) in Q4 2023, closing a stake of 85 shares — an estimated $2.1K sold.

C.M. Bidwell & Associates first reported a position in AGIO in Q2 2023 and held it in 2 quarters. The position peaked at $180K in Q2 2023. 169 funds tracked by Wall St. Rank hold AGIO as of Q4 2023.

  • C.M. Bidwell & Associates reported no remaining Agios Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 85 Agios Pharmaceuticals shares in Q4 2023, an estimated $2.1K.
  • C.M. Bidwell & Associates first reported a position in Agios Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Agios Pharmaceuticals position peaked at $180K in Q2 2023.
  • 169 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2023, filed 14 Feb 2024.